July 2, 2019 10:34 AM EDT
Deals
China

In­cyte flips Chi­na rights of Macro­Gen­ic­s' PD-1 to an am­bi­tious Zai Lab keen on leapfrog­ging pi­o­neers with com­bos

Amber Tong

Amid the pro­lif­er­a­tion of check­point in­hibitors in Chi­na, Zai Lab is bring­ing in one more PD-1 agent in a move to in­stall what has be­come …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

Mer­ck­'s PD-1xVEGF part­ner LaNo­va gets snapped up for $951M

FDA ques­tions safe­ty, ef­fi­ca­cy of GSK's Blenrep in mul­ti­ple myelo­ma ahead of ad­comm

Up­dat­ed: Af­ter Phase 3 obe­si­ty suc­cess, Hen­grui plans Chi­na ap­proval fil­ing for Kail­era-part­nered drug

The Trump ad­min­is­tra­tion dis­band­ed a new­born screen­ing pan­el. Ad­vo­cates now face a hard­er path

BMS warns against ‘in­dis­crim­i­nate use’ of rene­go­ti­a­tions as CMS plans next drug price talks

A service from the Financial Times